Rockefeller Capital Management
MRTX

Rockefeller Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Rockefeller Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-105
Closed -$4K – 4093
2022
Q4 		$4K Sell
105
-101
-49% -$6.54K ﹤0.01% 3412
2022
Q3 		$13K Sell
206
-99
-32% -$7.33K ﹤0.01% 2987
2022
Q2 		$20K Buy
305
+94
+45% +$5.98K ﹤0.01% 2761
2022
Q1 		$17K Buy
211
+19
+10% +$1.94K ﹤0.01% 2811
2021
Q4 		$28K Buy
192
+50
+35% +$7.76K ﹤0.01% 2485
2021
Q3 		$25K Sell
142
-7
-5% -$1.13K ﹤0.01% 2495
2021
Q2 		$24K Sell
149
-186
-56% -$29.9K ﹤0.01% 2412
2021
Q1 		$57K Sell
335
-180
-35% -$35.6K ﹤0.01% 1840
2020
Q4 		$113K Buy
515
+159
+45% +$34.4K ﹤0.01% 1395
2020
Q3 		$59K Buy
356
+311
+691% +$42.6K ﹤0.01% 1459
2020
Q2 		$5K Buy
+45
New +$4.36K ﹤0.01% 2120
2019
Q4 		– Sell
-1,153
Closed -$90K – 2248
2019
Q3 		$90K Buy
+1,153
New +$108K ﹤0.01% 826

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Rockefeller Capital Management's MRTX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 105 shares — an estimated $4K sold.

Rockefeller Capital Management first reported a position in MRTX in Q3 2019 and held it in 12 quarters. The position peaked at $113K in Q4 2020. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 105 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $4K.
  • Rockefeller Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 12 quarters.
  • Rockefeller Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $113K in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.